Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Goldenwell Biotech (GWLL) Equity Ratio (2019 - 2025)

Goldenwell Biotech filings provide 7 years of Equity Ratio readings, the most recent being 0.43 for Q3 2025.

  • On a quarterly basis, Equity Ratio fell 501.24% to 0.43 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.43, a 501.24% decrease, with the full-year FY2024 number at 0.21, down 156.73% from a year prior.
  • Equity Ratio hit 0.43 in Q3 2025 for Goldenwell Biotech, down from 0.35 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.89 in Q3 2022 to a low of 0.43 in Q3 2025.
  • Median Equity Ratio over the past 5 years was 0.65 (2021), compared with a mean of 0.41.
  • Biggest five-year swings in Equity Ratio: skyrocketed 30.61% in 2022 and later crashed 1909.98% in 2025.
  • Goldenwell Biotech's Equity Ratio stood at 0.65 in 2021, then grew by 24.01% to 0.81 in 2022, then plummeted by 54.24% to 0.37 in 2023, then plummeted by 156.73% to 0.21 in 2024, then tumbled by 104.17% to 0.43 in 2025.
  • The last three reported values for Equity Ratio were 0.43 (Q3 2025), 0.35 (Q2 2025), and 0.43 (Q1 2025) per Business Quant data.